Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Mervyn Israel"'
Publikováno v:
International Journal of Nanomedicine
Nirupama Sabnis1, Maya Nair1, Mervyn Israel2, Walter J McConathy3, Andras G Lacko11University of North Texas Health Science Center, Fort Worth, TX, 2University of Tennessee Health Science Center, Memphis, TN, 3Texas Tech University Health Sciences Ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffa9bbecce519faf229a7f4148ce7ea
http://europepmc.org/articles/PMC3289451
http://europepmc.org/articles/PMC3289451
Autor:
Ganesh R. Panta, Lakita G. Cavin, Mervyn Israel, Jennifer D. Bilyeu, Trevor W. Sweatman, Leonard Lothstein, Christina M. Barrett, Marcello Arsura, Eddie J. Turner
Publikováno v:
Molecular Pharmacology. 65:1038-1047
Nuclear factor kappaB (NF-kappaB) has been implicated in inducible chemoresistance against anthracyclines. In an effort to improve the cytotoxicity of anthracyclines while reducing their cardiotoxic effects, we have developed a novel class of extranu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3ff0f636ac6be2c31e238f0400221e
https://doi.org/10.1124/mol.65.4.1038
https://doi.org/10.1124/mol.65.4.1038
Publikováno v:
Drug Resistance Updates. 4:169-177
The anthracycline antibiotics doxorubicin (Adriamycin; DOX) and daunorubicin (DNR) continue to be essential components of first-line chemotherapy in the treatment of a variety of solid and hematopoietic tumors. The overall efficacies of DOX and DNR a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c9672a7a8a313b824ce3336c59570f
https://doi.org/10.1054/drup.2001.0201
https://doi.org/10.1054/drup.2001.0201
Autor:
Trevor W. Sweatman, D. Parker Suttle, J. Brent Roaten, Yoshihiro Koseki, Leonard Lothstein, Mervyn Israel
Publikováno v:
Biochemical Pharmacology. 60:1621-1628
N-Benzyladriamycin (AD 288) is a highly lipophilic, semi-synthetic congener of doxorubicin (DOX). Unlike DOX, which stimulates double-stranded DNA scission by stabilizing topoisomerase II/DNA cleavable complexes, AD 288 is a catalytic inhibitor of to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::688dbca446a9514e2b9d5d04718996ea
https://doi.org/10.1016/s0006-2952(00)00472-x
https://doi.org/10.1016/s0006-2952(00)00472-x
Publikováno v:
Cancer Chemotherapy and Pharmacology. 43:419-426
Purpose: N-Benzyladriamycin-14-valerate (AD 198) is a semisynthetic anthracycline analogue superior to doxorubicin (DOX) both in vitro and in experimental rodent tumor models, and with differing mechanistic properties from those of the parental antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::745c25397f50017edc34611c53a8dc56
https://doi.org/10.1007/s002800050917
https://doi.org/10.1007/s002800050917
Autor:
Gary D. Steinberg, Charles Bellingham, Mitchell Edson, Mervyn Israel, Peter J. O'Dwyer, Robert R. Bahnson, Darien Wood, Stacy J. Childs, Mitchell H. Bamberger, Bruce J. Giantonio, Trevor W. Sweatman, Richard E. Greenberg
Publikováno v:
Urology. 49:471-475
Objectives This study was designed to assess the pharmacokinetics, safety, and antitumor activity of intravesically administered AD 32, a novel anthracycline, in patients with transitional cell carcinoma (TCC) of the bladder. Methods Six weekly doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0949cf859a27770d39e475ace834d912
https://doi.org/10.1016/s0090-4295(96)00621-8
https://doi.org/10.1016/s0090-4295(96)00621-8
Publikováno v:
Cancer Chemotherapy and Pharmacology. 37:472-478
Lipophilic N-alkylanthracyclines such as AD 198 (N-benzyladriamycin-14-valerate) or AD 201 [N,N-di-(n-propyl)adriamycin-14-valerate], which exert their cytotoxicity through mechanisms which are not yet fully defined, possess inherent abilities to cir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d6d5dc902bdd53bfea3b066ebd7590
https://doi.org/10.1007/s002800050414
https://doi.org/10.1007/s002800050414
Autor:
Mervyn Israel, B. S. Jayashree, Chhabil Dass, K. N. Thimmaiah, Peter J. Houghton, Ramakrishnan Seshadri
Publikováno v:
Scopus-Elsevier
The mass spectral behavior of a set of eight 2- and 10-disubstituted phenoxazines putatively possessing anticancer drug enhancer properties was investigated. Both electron ionization (EI) and keV-ion beam bombardment (liquid secondary ion mass spectr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90299fbc931d5002d6965c4515f88ce2
https://doi.org/10.1002/bms.1200230304
https://doi.org/10.1002/bms.1200230304
Publikováno v:
Cancer Chemotherapy and Pharmacology. 28:1-6
Based on previous clinical findings following systemic administration, as well as appropriate laboratory evidence, the novel lipophilic anthracycline analogue N-Trifluoroacetyladriamycin-14-valerate (AD 32) has been identified as an agent of potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f84c82bdda1d27262d7eb2b83af927
https://doi.org/10.1007/bf00684948
https://doi.org/10.1007/bf00684948
Publikováno v:
Biochemical Pharmacology. 40:1441-1448
Adriamycin (ADR; doxorubicin) and its highly lipophilic, less toxic analogue N-benzyl-adriamycin-14-valerate (AD 198) were found to inhibit rat heart and liver carnitine palmitoyltransferases of both mitochondrial outer and inner membranes. The outer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc5fd100a8b347bd00b7f0bae7775413
https://doi.org/10.1016/0006-2952(90)90438-q
https://doi.org/10.1016/0006-2952(90)90438-q